1. Scrip

Takeda Takes Collaborative, Educational Approach In Thai Dengue Initiative

Ties Up With Kao

 
• By Lisa Takagi

As it looks to roll out its new dengue vaccine globally, Takeda will work with Kao’s Thai subsidiary on education and prevention activities in Bangkok, later expanding these to wider areas of Thailand, in the first such local collaboration by the private sector. 

Takeda and Kao will collaborate with Thai Gov't Organizations in combatting dengue
Takeda, Kao link on Thai dengue project as vaccine progresses • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. and chemical/cosmetics group Kao Corporation’s Thai subsidiary, Kao Industrial (Thailand) Co., Ltd., have announced a new collaboration with government organizations in Thailand for the nationwide prevention of dengue that builds on the two Japanese firms' respective products for the mosquito-borne disease.

The two companies signed a memorandum of understanding for Thailand Dengue Prevention and Control on 28 October, under which they will work together on prevention, education and control programs, although further details have not been disclosed at this stage

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.